Critical Therapeutics signs licensing deal for asthma drug

(Reuters) - The company has also agreed to make aggregate milestone
payments of up to $2.9 million to CyDex.




CyDex has been given a worldwide, exclusive license to
develop and sell Zileuton combined with or formulated using
Captisol, its patented drug enablement technology.


Read more at Reuters.com Government Filings News